Dark
Streaming/Mobile
Old Site
Home
Products
Help
Contact Us
Your Account
System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
00:50:45 EDT Sun 05 May 2024
Quotes
Streaming/Mobile
Quick Quotes (x20)
Symbol Search
Company Search
Market Depth
US Options
Montreal Options
Foreign Exchange
Download Close Prices
Short History
Quotes Help
Charts
12 Month Chart
Advanced Chart
Live Intraday Chart
Live Historical Chart
Live Java Intraday Chart
Live Java Historical Chart
Charts Help
News
News Search
SEDAR Search
SEDAR Alerts
News Help
Indexes
Major Indexes
US incl Dow Jones
NASDAQ
S&P CME
PBOT - Phil Ex
TSX - Toronto
TSX-V - TSX Venture
Indexes Help
Portfolio
View Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Value Portfolio
All Portfolios
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Edit Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Chart Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Live Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
View Portfolio News
Daily Summary
Portfolio Help
Analytics
Exchange Statistics
Most Active
Live Most Active
Block Trades
Broker Trades
Halted Stocks
Dividends
Participants
Companies
Trade Workstation
Company Picker
Short Positions
Broker Codes
Analytics Help
Mutual Funds
Mutual Fund Search
Targeted Holder Search
SEDAR Fund Search
Mutual Fund Help
Enter Symbol
or Name
USA
CA
Quote
Chart
News
Closes
Depth
Forgot password?
Trouble logging in?
Login to Stockwatch
Q:ALNY
- ALNYLAM PHARMACEUTICALS INC -
http://www.alnylam.com
00:50:45 EDT
Sym-X
Bid - Ask
Last
Chg
%Ch
Vol
$Vol
#Tr
Open-Hi-Lo
Year Hi-Lo
Last Tr
News
Delay
ALNY
- Q
0.2
150.53
·
155.00
1.0
152.33
+2.02
1.3
452.2
68,627
9,249
154.41
155.41
151.84
218.88 141.975
17:30:07
May 02
15 min
RT 2¢
Trade times are ET. News times are ET. Bid/ask/vol sizes in thousands.
Nasdaq Indicators -- Market:
Nasdaq
-- Bid Tick:
Down
-- UPC Restricted:
No
Fundamentals
·
Holders
·
Trade Workstation
·
Market Depth
·
3 Month Closes
·
Technical Charts
1 yr
|
2 yr
|
3 yr
|
5 yr
|
10 yr
|
15 yr
|
20 yr
·
Live Charts
1 yr
|
1 day
·
1yr Bulletins
·
Historical
·
Options
·
Portfolio
Recent Trades - Last 10 of 9249
More trades...
Time ET
Ex
Price
Change
Volume
17:30:07
Q
152.77
2.46
1
16:42:08
Q
152.8457
2.5357
1
16:34:46
Q
146.74
-3.57
1
16:20:00
Q
152.33
2.02
152
16:01:39
Q
152.33
2.02
22
16:01:37
Q
152.33
2.02
297
16:01:20
Q
152.33
2.02
4
16:01:11
Q
152.33
2.02
8
16:00:55
Q
152.33
2.02
83
16:00:48
Q
152.33
2.02
104
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
Recent Bulletins
News Releases
In The News
Other
Date ET
Symbol
Type
Headline
2024-05-02 08:00
U:ALNY
News Release
200
Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity
2024-04-30 07:00
U:ALNY
News Release
200
Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia
2024-04-18 08:00
U:ALNY
News Release
200
Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results
2024-04-07 08:00
U:ALNY
News Release
200
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension
2024-03-20 08:00
U:ALNY
News Release
200
Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session
2024-03-13 07:30
U:ALNY
News Release
200
Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease
2024-03-05 07:30
U:ALNY
News Release
200
Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives
2024-02-27 08:30
U:ALNY
News Release
200
Alnylam to Webcast Presentations at Upcoming March Investor Conferences
2024-02-15 08:00
U:ALNY
News Release
200
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Period Activity
2024-01-29 08:00
U:ALNY
News Release
200
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2023 Financial Results
2024-01-09 08:05
U:ALNY
News Release
200
Alnylam CEO Yvonne Greenstreet Named 2024 Woman of the Year by Healthcare Businesswomen ¢ € ™s Association
2024-01-07 18:00
U:ALNY
News Release
200
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2023 Global Net Product Revenues and Provides Additional Updates
2024-01-02 07:30
U:ALNY
News Release
200
Alnylam to Webcast Presentation at 42nd Annual J.P. Morgan Healthcare Conference
2023-12-13 07:30
U:ALNY
News Release
200
Alnylam Highlights Significant Progress with Platform Innovation and Clinical Pipeline at R&D Day
2023-12-06 08:00
U:ALNY
News Release
200
Alnylam to Webcast Virtual R&D Day
2023-11-30 08:00
U:ALNY
News Release
200
Alnylam Ranks #1 on Boston Globe ¢ € ™s Top Places to Work List for 2023
2023-11-11 16:00
U:ALNY
News Release
200
Alnylam Presents Positive Results from the KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hypertension in Patients at High Cardiovascular Risk
2023-11-07 08:00
U:ALNY
News Release
200
Alnylam to Webcast Presentations at Upcoming November Investor Conferences
2023-11-02 08:00
U:ALNY
News Release
200
Alnylam Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Period Activity